[A18-39] Lumacaftor/ivacaftor (cystic fibrosis) - Addendum to Commission A18-08

Last updated 03.08.2018

Project no.:
A18-39

Commission:
Commission awarded on 13.06.2018 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Digestion, metabolism and hormones

Indication:

Cystic fibrosis (CF) in 6 to 11 year old children who are homozygous for the F508del mutation in the CFTR gene

Result of dossier assessment:

Conclusion of dossier assessment A18-08 unchanged

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2018-08-02 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form